- $40.52m
- $22.11m
- $0.05m
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Inc expected to post a loss of 38 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, gold miners
U.S. STOCKS ON THE MOVE-Tyson Foods, BioNTech, Gold miners
INmune Bio rises as prostate cancer therapy meets trial goals
Brief: INmune Bio’s INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints
INmune Bio Inc expected to post a loss of 38 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
U.S. STOCKS ON THE MOVE-Snap, Solventum, GlobalFoundries
Scotiabank double downgrades rating on INmune Bio after Alzheimer's drug failure
U.S. STOCKS ON THE MOVE-NIP Group, Hyatt, BioXcel Therapeutics
U.S. STOCKS ON THE MOVE-Circle, gold miners, silver miners
Scotiabank double downgrades rating on INmune Bio after Alzheimer's drug failure
Scotiabank double downgrades rating on INmune Bio after Alzheimer's drug failure
U.S. RESEARCH ROUNDUP-First Citizens Bancshares, Oracle, PPG Industries
Brief: Inmune Bio Closes nearly $19M At-Market Registered Direct Offering Under Nasdaq Rules
U.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings
U.S. STOCKS ON THE MOVE-Lamb Weston, Robinhood, Eve Holding
INmune Bio hits record low as Alzheimer's drug misses mid-stage trial goal